Momelotinib

Introduction Overview

Generic Name

momelotinib

Brand Name

Ojjaara

Dosage Form

oral tablet

Drug Class

Multikinase inhibitors (Janus Kinase inhibitor)

Pharmacokinetics

Absorption:
Momelotinib is orally administered and absorbed via the gastrointestinal tract. After oral dosing, momelotinib exhibits moderate bioavailability with peak plasma concentrations generally observed within 2 to 4 hours post-dose. Food does not significantly affect the extent of absorption, allowing administration with or without food to optimize patient convenience. The absorption process may be influenced by gastrointestinal motility and pH; however, no clinically meaningful interactions with acid-reducing agents have been documented.

Distribution:
Momelotinib demonstrates moderate plasma protein binding, primarily to albumin, which impacts its distribution volume. The drug distributes extensively into tissues, including bone marrow, the primary site of action in myelofibrosis treatment. The ability of momelotinib to penetrate inflammatory and hematopoietic tissues is critical to its therapeutic effects. Volume of distribution values approximate 150–200 L, indicating extensive extravascular distribution.

Metabolism:
Momelotinib is extensively metabolized primarily by hepatic enzymes, predominantly involving the cytochrome P450 system (notably CYP3A4). The metabolic process produces several metabolites, some of which are pharmacologically active. Enzymatic metabolism also involves conjugation pathways with minor contributions. Hepatic impairment affects momelotinib clearance, necessitating dose adjustments in patients with severe liver dysfunction. Drug-drug interactions via CYP3A4 modulation (inhibitors or inducers) may impact plasma concentrations.

Elimination:
Elimination of momelotinib involves both renal and fecal routes, with approximately 30–40% excreted unchanged in feces and a lesser amount via urine. The elimination half-life ranges from approximately 15 to 25 hours, supporting once-daily dosing regimens. Steady-state concentrations are typically achieved within 7 days of dosing. Impaired renal function has minimal impact on the pharmacokinetics, but severe hepatic impairment may require dose modification. Monitoring of plasma levels is not routine but may be considered in cases with significant hepatic dysfunction or polypharmacy.

Dosage Forms

Available Dosage Forms:
Ojjaara is available as oral tablets in three strengths to accommodate dose adjustments based on patient tolerance and clinical response:
- Ojjaara 100 mg tablets
- Ojjaara 150 mg tablets
- Ojjaara 200 mg tablets
Each tablet incorporates a film coating composed of polyethylene glycol, polyvinyl alcohol, and iron oxides for color, ensuring stability and patient compliance.

Dosages for Adults and Adolescents:
The recommended starting dose for adults with myelofibrosis-associated anemia is 200 mg once daily. Dose modifications may be considered based on tolerability, adverse effects, and hepatic function status. For patients with severe liver disease (Child-Pugh Class C), dose reduction is advised to mitigate toxicity risks. The tablet should be swallowed whole without chewing or crushing to preserve drug integrity.

Specific Patient Populations:
- Hepatic Impairment: Dose reduction is recommended in severe hepatic impairment due to altered metabolism and increased exposure.
- Renal Impairment: No significant dose adjustments are required, though clinical monitoring is advised.
- Pediatric Use: Safety and efficacy have not been established in children; thus, use is not indicated.
- Geriatric Use: No dose adjustment required solely on age; however, close monitoring is recommended due to potential comorbidities.
- Pregnancy and Lactation: Use is contraindicated during pregnancy unless benefits outweigh risks; breastfeeding is not recommended during treatment and for 1 week after last dose.

Mechanism Of Action

Ojjaara (momelotinib) exerts its therapeutic effects primarily through selective inhibition of the Janus kinase (JAK) family enzymes, specifically JAK1 and JAK2, as well as the mutant form of JAK2 (JAK2V617F), which is commonly implicated in myeloproliferative disorders such as myelofibrosis. These kinases are integral components of the JAK-STAT signaling pathway, which transduces signals from cytokine receptors to influence gene expression critical for hematopoiesis and immune regulation.

By reversibly inhibiting JAK1 and JAK2, momelotinib disrupts aberrant signaling cascades that lead to excessive proliferation and dysregulated function of hematopoietic cells. This blockade reduces the pathological expansion of fibrotic and neoplastic cells in the bone marrow and helps restore equilibrium in blood cell production, addressing anemia and splenomegaly associated with myelofibrosis.

Furthermore, momelotinib's interaction with the mutant JAK2V617F variant specifically targets the constitutively active kinase, reducing pathological cytokine signaling without broadly suppressing normal hematopoietic function. This selectivity underpins its favorable safety profile compared to non-selective cytotoxic agents.

Clinical studies have demonstrated that momelotinib not only alleviates symptoms by modulating inflammatory cytokines but also improves anemia in patients, likely due to effects on hepcidin regulation mediated through JAK-STAT signaling. Compared with other JAK inhibitors such as ruxolitinib and fedratinib, momelotinib uniquely contributes to anemia improvement in myelofibrosis patients, expanding therapeutic options. Ongoing research continues to elucidate precise molecular interactions and optimize patient selection for therapy.

Pharmacological Actions

Selective inhibition of Janus kinases JAK1 and JAK2, including the mutant JAK2V617F.
Modulation of the JAK-STAT signaling pathway to regulate hematopoietic cell proliferation and differentiation.
Reduction of abnormal cytokine signaling contributing to inflammation and bone marrow fibrosis.
Improvement of anemia by influencing hepcidin levels and iron homeostasis.
Reduction of splenomegaly through suppression of pathological hematopoietic cell expansion.
Targeted antineoplastic activity without the widespread cytotoxicity of traditional chemotherapy.
Immunomodulatory effects via decreased pro-inflammatory cytokine production.
Potential reduction in symptom burden related to myeloproliferative neoplasms.
Selective targeting minimizes off-target effects on non-hematopoietic tissues.
Oral bioavailability enabling convenient once-daily dosing for patients.
Demonstrated efficacy in reducing spleen size and improving quality of life in clinical trials.

Therapeutic Or Clinical Uses

Treatment of adults with primary myelofibrosis (PMF).
Management of post-polycythemia vera (post-PV) myelofibrosis.
Management of post-essential thrombocythemia (post-ET) myelofibrosis.
Treatment of myelofibrosis patients with anemia, improving red blood cell counts.
Reduction of splenomegaly associated with myelofibrosis.
Symptom amelioration in myelofibrosis including fatigue, night sweats, and bone pain.
Use as a targeted therapy for patients harboring the JAK2V617F mutation.
Alternative therapeutic option for patients intolerant or refractory to other JAK inhibitors.
Potential investigational utility in other myeloproliferative neoplasms under clinical study.
Adjunct therapy in comprehensive myelofibrosis management protocols.

Side Or Adverse Effects

Thrombocytopenia (low platelet counts) leading to increased bleeding risk.
Dizziness and lightheadedness, potentially impacting balance and coordination.
Bleeding manifestations including bruising, petechiae, and gastrointestinal bleeding.
Diarrhea and other gastrointestinal disturbances such as nausea and vomiting.
Increased susceptibility to bacterial infections including severe and fatal infections.
Fatigue and general tiredness affecting patient quality of life.
Elevation of liver enzymes and bilirubin indicating hepatotoxicity.
Serious adverse events including major cardiovascular events such as myocardial infarction and stroke.
Potential for development of blood clots, including deep vein thrombosis and pulmonary embolism.
Risk of reactivation of latent hepatitis B infection.
Potential emergence of secondary malignancies including lymphoma.
Hypersensitivity reactions including allergic responses to active or inactive components.
Possible hematologic toxicities such as neutropenia and anemia exacerbation in some patients.
Rare but serious injection site reactions are not applicable due to oral administration but monitoring for unexpected adverse sites may be needed.
General adverse effects common to kinase inhibitors including headache and edema.

Precautions

Monitor complete blood counts regularly to detect and manage cytopenias early.
Screen for active infections prior to initiation; avoid starting therapy if infection present.
Evaluate liver function tests routinely to identify hepatotoxicity promptly.
Avoid use in patients with known hypersensitivity to momelotinib or tablet excipients.
Use cautiously in patients with cardiovascular risk factors or history of thromboembolic events.
Counsel patients on symptoms of infection and bleeding for early recognition.
Avoid live vaccines during treatment and until immune function normalizes upon cessation.
Adjust dose in patients with severe hepatic impairment (Child-Pugh Class C).
Assess for potential drug interactions especially with OATP1B1/B3 inhibitors and BCRP substrates.
Advise contraceptive measures during treatment and for at least one week after the last dose.
Breastfeeding is not recommended due to unknown excretion in human milk.
Use with caution in patients with a history of malignancies excluding non-melanoma skin cancer.
Special monitoring in patients with prior hepatitis B infection for possible reactivation.
Monitor for cardiovascular events and counsel patients to seek immediate care for relevant symptoms.
Consider dose interruption or discontinuation if severe adverse reactions occur.

Warnings

Risk of serious and sometimes fatal infections including bacterial, viral, and opportunistic pathogens.
Potential for severe hematologic toxicities including thrombocytopenia and neutropenia.
Risk of hepatotoxicity manifested as elevated liver enzymes and bilirubin; monitor liver function closely.
Increased risk of major cardiovascular events such as myocardial infarction and stroke, especially in patients with pre-existing heart disease or smokers.
Possibility of blood clots in veins (deep vein thrombosis) or lungs (pulmonary embolism), which may be life-threatening.
Potential activation of latent hepatitis B infection requiring screening and monitoring.
Possible development of new cancers, including lymphoma and other malignancies, with increased risk in smokers.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Pregnancy Category: May cause fetal harm; use effective contraception during treatment and for one week afterward.
Breastfeeding is contraindicated during treatment and for one week following the last dose.
Risk of worsening anemia or other cytopenias during therapy requiring careful hematological monitoring.
Drug interactions may increase toxicity risk; thorough medication review is necessary.
Avoid abrupt discontinuation to prevent potential disease rebound or adverse effects.
Electrolyte disturbances and other laboratory abnormalities require regular monitoring.
Use with caution in patients scheduled for vaccination; consult healthcare provider.

Contraindication

Known hypersensitivity to momelotinib or any component of Ojjaara tablets.
Active, uncontrolled infections at treatment initiation.
Pregnancy unless the potential benefit justifies the risk to the fetus.
Severe hepatic impairment without capacity for dose adjustment and intensive monitoring.
Use with other Janus kinase inhibitors concurrently due to overlapping toxicities.
History of severe allergic reactions to similar kinase inhibitors.
Breastfeeding during treatment and for one week following the last dose.
Conditions predisposing to uncontrolled bleeding or hemorrhage.
Concomitant use of potent OATP1B1/B3 inhibitors or BCRP substrates without dose adjustment.
Patients with known or suspected malignancies where treatment may exacerbate disease.
Severe immunodeficiency syndromes where infection risk is prohibitive.
Known cases of prolonged QTc interval and cardiac arrhythmias without adequate management.
Inability to comply with monitoring requirements and treatment adherence.
Use in pediatric population due to lack of established safety data.
Other contraindications detailed in the prescribing information as updated.

Drug Interactions

Inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1 and 1B3 such as atazanavir, clarithromycin, cobicistat, and cyclosporine may increase momelotinib plasma concentrations.
Substrates of Breast Cancer Resistance Protein (BCRP) including prazosin, sulfasalazine, and rosuvastatin may have altered pharmacokinetics when co-administered with momelotinib.
Concomitant use with other Janus kinase inhibitors likely increases risk for additive toxicity and is generally advised against.
CYP3A4 inhibitors may elevate momelotinib levels, enhancing risk of adverse effects.
CYP3A4 inducers can reduce momelotinib efficacy by lowering plasma drug concentrations.
Potential interactions with immunosuppressants and drugs affecting hematopoiesis exist and warrant close monitoring.
Concurrent anticoagulant or antiplatelet therapy may increase bleeding risk when combined with momelotinib.
Co-administration with live vaccines is contraindicated due to immunosuppressive effects.
Herbal supplements such as St. John's Wort, a CYP3A4 inducer, may reduce therapeutic effectiveness.
Avoid strong inhibitors or inducers of hepatic enzymes without dose adjustment or monitoring.
Monitor for enhanced toxicities when combined with other drugs that cause liver enzyme elevation.
Drugs affecting bile acid transporters may interfere with momelotinib elimination.
Potential interference with P-glycoprotein substrates needs consideration.
Consult comprehensive interaction databases and prescribing information for updates and less common interactions.
Maintain updated medication lists and communicate all therapies to healthcare providers to prevent adverse interactions.

Preparations Of The Drug

Ojjaara 100 mg oral tablets containing momelotinib dihydrochloride monohydrate.
Ojjaara 150 mg oral tablets containing momelotinib dihydrochloride monohydrate.
Ojjaara 200 mg oral tablets containing momelotinib dihydrochloride monohydrate.
Tablets coated with a film consisting of polyethylene glycol, polyvinyl alcohol, red and yellow iron oxides, talc, and titanium dioxide to ensure stability and patient compliance.
Inactive ingredients include lactose monohydrate, magnesium stearate, microcrystalline cellulose, propyl gallate, silicon dioxide, and sodium starch glycolate.
Packaged in moisture-protective bottles with desiccant packets to maintain stability during storage.
Storage recommended at room temperature (20°C to 25°C; 68°F to 77°F) in original container tightly closed.
Bottles labeled with dosing information and expiry dates for clinical safety.
Manufactured under strict Good Manufacturing Practice (GMP) standards by GlaxoSmithKline (GSK).
Patient information leaflets included providing detailed instructions for use, side effects, and precautions.
Available through prescription only to ensure proper clinical oversight.
Periodic batch testing done to assure potency and purity per regulatory guidelines.
Intended strictly for oral administration; not formulated for parenteral or alternative routes.
Imprint codes on tablets facilitate identification and prevent medication errors.
Packaging designed to support safe dispensing and minimize contamination risk.